Literature DB >> 16227692

Serial cytokine profiles in shunt-related ventriculitis treated with intraventricular vancomycin.

Gary Laborada1, Florencia Cruz, Mirjana Nesin.   

Abstract

BACKGROUND: A 1-month-old premature infant developed persistent shunt-related methicillin-resistant Staphylococcus aureus ventriculitis that was not responsive to parenteral therapy with vancomycin plus gentamicin (or rifampin).
METHODS: The infant was treated by intraventricular administration of vancomycin (5 days: 10 mg/day). In addition to standard testing of the cerebrospinal fluid (CSF), tumor necrosis factor alpha, interleukin-8 and interleukin-6 were serially measured.
RESULTS: Sterilization of the CSF was followed by a decline in the number of WBC and proinflammatory cytokines in the CSF.
CONCLUSION: Intraventricular administration of antibiotics may be considered if ventriculitis is refractory to systemic antimicrobial therapy. Serial measurements of inflammatory cytokines in the CSF may provide an additional diagnostic tool to monitor the outcome of therapy. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227692     DOI: 10.1159/000088963

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  2 in total

1.  Tumor necrosis factor alpha and interleukin-1 beta levels in cerebrospinal fluid examination for the diagnosis of ventriculoperitoneal shunt-related ventriculitis.

Authors:  Semih K Olguner; Bulent Boyar; Derya Alabaz; Tahsin Erman; Kadir Oktay; Ali Arslan; Emre Bilgin; Ali Ihsan Okten
Journal:  Childs Nerv Syst       Date:  2019-01-28       Impact factor: 1.475

2.  Host gene expression profiling and in vivo cytokine studies to characterize the role of linezolid and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) murine sepsis model.

Authors:  Batu K Sharma-Kuinkel; Yurong Zhang; Qin Yan; Sun Hee Ahn; Vance G Fowler
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.